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Introduction  37 
Ovarian depletion of primordial follicles is a continual natural process from gestation to adulthood, 38 
which culminates in the loss of ovarian function and which eventuates in the state of menopause (1, 39 
2). When activated, the primordial follicles grow and develop into small antral follicles, the majority 40 
of which succumb to apoptosis (3, 4). At puberty, cyclic increases in circulating follicle stimulating 41 
hormone (FSH) recruit a cohort of small antral follicles at the start of each menstrual cycle (3, 5). 42 
The follicles grow under the influence of FSH, and express follicle stimulating hormone receptor 43 
(FSHR) and luteinizing hormone receptor (LHR). The activation of FSH and the FSHRs stimulates 44 
oestrogen synthesis, which subsequently stimulates proliferation of the granulosa cells and 45 
development of the oocyte. (6-9). 46 
 47 
The ovulation rate is determined by the stage-specific decrease in pituitary secreted FSH, and results 48 
in follicles with insufficient LHRs that succumb to apoptosis (10-12). The follicle continues to grow 49 
until pre-ovulatory maturation when proliferation ceases and granulosa cell differentiation occurs in 50 
preparation for ovulation of the oocyte. 51 
 52 
As the ovarian reserve of primordial follicles is depleted over the reproductive lifespan, regulation of 53 
folliculogenesis is altered, which results in decreased fertility (13). Ovarian depletion can be 54 
indirectly measured by the number of small antral follicles present at the beginning of a cycle, and is 55 
highly correlated to chronological age (14). During IVF treatment, high doses of recombinant human 56 
(r) FSH are administered to recruit more of the small antral follicles, and to maintain their growth 57 
during pituitary FSH down-regulation (15).  58 
 59 
Infertility patients with a poor ovarian reserve have fewer small antral follicles available for 60 
recruitment, and higher doses of rFSH are used but with diminishing effectiveness in recruiting more 61 
follicles during IVF cycles. In an attempt to improve the pregnancy rate, patients have been offered 62 
co-treatment with growth hormone (GH) (15, 16). The patients with a poor response to rFSH 63 
treatment represent a large group of patients with critically diminishing ovarian reserve (17, 18). The 64 
challenge remains to identify the changes taking place as the ovarian reserve declines, and to find 65 
alternative stimulation to provide high quality oocytes for fertilisation.  66 
 67 
Earlier studies showed GH treatment in vivo and in vitro, in conjunction with rFSH increased oocyte 68 
survival rate and pregnancy rate (19-22). The granulosa cells, including cumulus cells, as well as the 69 
oocyte of antral follicles express growth hormone receptor (GHR) and are therefore able to react to 70 
pituitary-derived or ovarian sources of GH (23, 24). With regard to the latter, granulosa cells and the 71 
oocyte, but not cumulus and theca cells, have been shown to express GH mRNA (23-27). GHRs are 72 
activated by GH, which changes the conformation of the receptor, promoting formation of a complex 73 
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with janus kinase (JAK)2 (28). The GHR-JAK2 complex can elicit numerous cellular responses in 74 
the body, such as cell differentiation and oocyte maturation in the ovary (29).  75 
 76 
The cellular mechanism underpinning the GH-induced improvement in oocyte quality and reduced 77 
miscarriage rate has not been reported in human studies. However, many attempts have been made to 78 
delineate the indirect changes taking place to serum and follicular fluid hormone levels. Previously, 79 
we have presented comprehensive results on the granulosal cell surface receptor density profiles of 80 
patients during ovarian ageing (30, 31). Ovarian granulosa cell receptor expression was found to 81 
fluctuate at the two critical times of dominant follicle selection and again at the terminal end of 82 
folliculogenesis in preparation for ovulation. Lower levels of receptor density and a reversal of this 83 
regulatory pattern was associated with reduced fertility and ovarian reserve in older patients. In the 84 
present study, we report the granulosal GHR density in different sized follicles from IVF patients 85 
undergoing conventional ovarian stimulation, with rFSH alone and with rFSH combined with GH co-86 
treatment in young compared to older women with a reduced ovarian reserve. In addition, we report 87 
the granulosal FSHR, LHR, and BMPR1B receptor density in older, poor ovarian reserve patients 88 
treated with GH. 89 
Materials and Methods  90 
Patients 91 
Patients (women) were selected randomly in a prospective regimen, and aged between 23 and 45 92 
years, with a range of infertility factors, but limited to exclude unusual medical conditions, endocrine 93 
dysfunction, polycystic ovarian syndrome and endometriosis. Infertility issues were comprised of 94 
male factor, low ovarian reserve, donor sperm or unexplained fertility; and fertilisation was via 95 
intracytoplasmic sperm injection (ICSI). A total of 483 follicles were collected from 64 patients 96 
undergoing standard fertility treatment at PIVET Medical Centre Perth, Western Australia, (Table 1). 97 
 98 
Human IVF: Ovarian stimulation, follicular fluid, and oocyte 99 
Patient treatment consisted of two types of gonadotrophin releasing hormone-LH suppression 100 
(Orgalutran; MSD and Cetrotide; Merck Serono) in conjunction with commercially prepared 101 
recombinant human (r) FSH (Puregon; MSD and Gonal-f; Merck Serono), from cycle day 2 for ~10 102 
days, as described by Regan et al. (2015). Ovulation was triggered with 10 000 IU human chorionic 103 
gonadotrophin (hCG: Pregnyl; MSD), and oocyte retrieval was 36 hours later by transvaginal oocyte 104 
aspiration (30). Patients classified as poor prognosis due to poor ovarian response or with three or 105 
more failed attempts to conceive through IVF treatment with gonadotrophin alone, were co-treated 106 
with a total of 60 IU GH (Saizen, Serono, Australia) over a period of 20-24 days in the lead-up to 107 
IVF. GH was administered to 11 patients starting on day 21 of the previous cycle, and on day 2, 6, 8, 108 
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10, and 12 (10 IU per injection, a total of 60 IU) of the current cycle to women aged ≥39 years who 109 
had at least one failed IVF cycle (15).  110 
 111 
Antral follicle count  112 
Patients received daily rFSH according to a long established algorithm based on the patient’s profile 113 
of age and ovarian reserve in order to determine the rFSH dose required to stimulate 8-12 114 
preovulatory follicles, (32). Ovarian reserve was measured indirectly by the antral follicle count, and 115 
was defined as the number of follicles between 2-10 mm in diameter, combining the number 116 
collected from both ovaries; that were present on ~day 5 of a preliminary assessment cycle, without 117 
rFSH (14). The patients were divided by age and ovarian reserve  into groups based on the algorithm, 118 
as described previously by Regan et al. (2016) and a well-established clinical practice of patient 119 
treatment (32, 33): Group A+ = 30-39 small follicles; group A = 20-29 small follicles; group B = 13-120 
19 small follicles; group C = 9-12 small follicles, group D = 5-8 small follicles; group E = ≤ 4 small 121 
follicles. 122 
Immunolabelling of granulosa cells 123 
The ovarian follicles studied ranged in diameter from 4 to 27 mm, and an average of ~8000 124 
granulosa cells per individual follicle were analysed. Cell surface-expressed mature GHR protein 125 
density was measured by immunofluorescent labelling and flow cytometry. The diameter of the 126 
follicle was calculated using ultrasonography as described previously (30, 31, 34). Flushing of the 127 
follicle (Quinn’s Advantage with Hepes, Sage Media, Pasadena, California) removed the loosely 128 
attached layers of granulosa cells. Aliquots of suspended granulosa cells (1x10⁶ cells in 100 µl) were 129 
immunolabelled and incubated separately with an optimised concentration of 4 µg/ml affinity 130 
purified polyclonal antibody to bone morphogenetic hormone receptor (BMPR1B), FSHR, LHR or 131 
GHR for 25 min at 5 ˚C.  132 
3D image analysis using immunofluorescence detection has established the specificity of the 133 
antibodies in sheep, polyclonal goat anti-BMPR1B (sc-5679), goat anti-FSHR (sc-7798), and goat 134 
anti-LHR (sc-26341) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), (35); and GHR (AF1210; 135 
Life Technologies, Victoria, Australia) (36). In addition, use of these antibodies has been previously 136 
reported in human studies (37-44) and for use in flow cytometry (38). The cells were washed with 137 
PBS and centrifuged at 300 g at 5˚C for 5 min. To render a homogeneous population of granulosa 138 
cells the monoclonal antibody CD45 was added to BMPR1B, GHR, and LHR tubes to enable the 139 
subtraction of the positive leukocyte common antigen (~ 3%) not removed during isolation of the 140 
granulosa cells with the ficoll gradient (555485; BD Biosciences, Perth, Australia), (Fig. 1A and 1B). 141 
 142 
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Unstained samples or the substitution of a primary antibody with pre-immune goat IgG (Millennium 143 
Science, Surrey Hills, Victoria Australia) at the same concentration as the primary antibody served as 144 
a negative control for auto-fluorescence (Fig. 1A). A blocking peptide for FSH receptor and bone 145 
morphogenetic protein receptor 1B indicated nonspecific binding applied to human granulosa cells 146 
(sc-7798P, sc-5679P; Millennium Science, Surrey Hills, Victoria Australia), (Fig. 1B), and as 147 
previously published (37, 38). Pre-absorbed LH (Lutropin, Merck Serono, Frenchs Forest, NSW, 148 
Australia), and GH (Saizen, Merck Serono, Australia) also confirmed binding specificity. In the 149 
current study, the ‘normal’ goat IgG and unstained control cells emitted an average mean fluorescent 150 
intensity (MFI) that was classified as non-specific auto-fluorescence. The auto-fluorescence and the 151 
nonspecific binding determined by the unstained control for each follicle was subtracted from each 152 
follicle (Fig. 1B), and as described previously (30, 31).  153 
Re-suspended 10µl aliquots of GHR immunolabelled, live granulosa cells were placed on slides and 154 
visualized using an Olympus DP 70 camera fitted to an Olympus BX-51 upright fluorescent 155 
microscope with a 40x UPlan N 0.4 N.A. objective (Olympus Imaging Australia, Macquarie Park, 156 
Australia), (Fig.1C). Fluorescent microscopy revealed a positive staining of the cell membrane-157 
bound GHR as an intermittent, bright, ring-like pattern around the cells (Fig .1C). Pre-absorbed GH 158 
was used as a negative control. A pure granulosa cell population was identified by graphing forward 159 
scatter to remove doublets (FSC-H verses FSC-A), as previously described (30, 31, 34). The uniform 160 
granulosa cell population revealed positive staining for FSHR, which is unique to granulosa cells 161 
(45). The data were analysed using FlowJo software (Tree Star Inc., Oregon, USA).  162 
 163 
Serum and Follicular fluid assessment 164 
The peak oestrogen concentration in serum was used to predict the follicular health of the follicle as 165 
opposed to the serum levels collected at the time of follicle aspiration. Serum was analysed using 166 
biochemical analysis on the days leading up to collection and on the day of collection. IVF patients 167 
undergoing treatment were examined in a natural cycle and during exogenous rFSH stimulated 168 
cycles. Follicular fluid collected from follicles 17 to 23 mm were analysed for testosterone, FSH, and 169 
LH using a random access immunoassay system (Siemens Medical Solutions, Bayswater, Victoria, 170 
Australia). Follicular fluid, testosterone, FSH, and LH were analysed undiluted, whereas oestrogen 171 
and progesterone were diluted manually 1:1000 with a multi-diluent and, when required, a further 172 
manual dilution of progesterone 10 x and oestrogen; 5 x. Percentage coefficient of variance (CV) for 173 
a concentration range 137.4 pmol/L to 3257 pmol/L was oestrogen = 5.2; LH = 3.9; FSH = 2.9; 174 
testosterone = 5.9; progesterone = 9.4. 175 
 176 
Statistics 177 
Mean fluorescent intensity was obtained using ~8000 granulosa cells per individual follicle for the 178 
direct measurement of receptor protein expression. The data were subjected to statistical verification 179 
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using one-way ANOVA with an uncorrected Fisher’s LSD for follicular size using GraphPad Prism 180 
6. Values in graphs are means ± S.E.M., and differences were considered significant if *p<0.05, 181 
**p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’, signifies a statistical significant 182 
difference to the matching letter (e.g. ‘a*’). The attached asterisk (a*) indicates the significance level 183 
for the size follicle. A two tailed, student t-test and chi squared was also used. 184 
Human Ethics 185 
Patients undergoing standard fertility treatment at PIVET Medical Centre, Perth, Australia provided 186 
informed consent according to Curtin University Human Research Committee (HR RD26-10:2010 187 
and 2016); and all methods were performed in accordance with the relevant guidelines and 188 
regulations under State Legislation and National Accreditation processes. 189 
 190 
Results 191 
GHR density without growth hormone co-treatment and ovarian reserve depletion 192 
In the youngest patients with good ovarian reserve, a constant level of granulosal GHR was 193 
expressed during follicular growth in both the A+ and A groups, both of which are typical for a 194 
patient in this age group (Fig. 2A).  195 
 196 
GHR density was significantly decreased as the ovarian reserve was depleted in all of the three older 197 
age groups. In the 31-34 y patient group, GHR density on the granulosa cells from follicles of the 198 
same size was significantly reduced in the patients with a reduced ovarian reserve for the age group 199 
(p=0.039, 14 mm follicles; 0.0037, 16 mm follicles, Fig. 2B). This trend was also found in the 35-38 200 
y patient group; (p=0.029, 4 mm follicles;, Fig. 2C) and in the 39+ y patient group (p=0.0001, 4 mm 201 
follicles; p=0.0012 14 mm follicles, Fig. 2D).  In the older patients (39+ y), with a comparatively 202 
better ovarian reserve of B or C, the level of GHR was significantly reduced in the larger follicles to 203 
the level observed in the poorer D and E ovarian reserve group (p<0.001; Fig. 2D). 204 
 205 
GHR receptor density profile independent of patient age  206 
The patient data were analysed based on ovarian follicle reserve, independent of chronological age 207 
(Suplemetary Fig. 1). In patients with good ovarian reserve, an initial high level of  GHR in the 208 
smaller follicles was followed by a decline as the follicles increased in size (14 to 23 mm follicles, 209 
p=0.0005). This pattern was reversed in the poorer ovarian reserve patient groups of D & E (p<0.05). 210 
Granulosal GHR receptor density was greater in the 10 mm (p<0.01) and 14 mm (p<0.005)  follicles 211 
in the good ovarian reserve patient group compared to patients with the poorest ovarian reserve 212 
(Suplemetary Fig. 1).  213 
 214 
Growth hormone co-treatment restores preovulatory down-regulation of FSHR 215 
BMPR1B and LHR 216 
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The level of GHR was significantly increased in IVF patients receiving GH co-treatment in follicles 217 
from 10 to 23 mm compared to the same age patients of 39+ y with an ovarian reserve of  D & E 218 
(p<0.01 to p<0.001, Fig.3A). The level of GHR expression in different sized follicles was not 219 
significantly different in patients treated with GH (Fig 4A).  220 
 221 
The level of FSHR was significantly increased in IVF patients receiving GH in 16 mm follicles 222 
compared to the same age patients of 39+ y with an ovarian reserve of D & E without GH (p<0.001, 223 
Fig.4B).The level of FSHR in GH treated patients was also increased in the larger follicles from 4 224 
mm to 16 mm (Fig. 3B, p<0.005). This was followed by a significant down-regulation of the largest 225 
preovulatory follicles (p<0.01, 19 mm).  226 
 227 
The level of LHR was significantly increased in IVF patients receiving GH in 16 mm follicles 228 
compared to the same age patients of 39+ y with an ovarian reserve of D & E without GH (p<0.005, 229 
Fig.4C). The LHR density of the granulosa cells collected from patients who received GH co-230 
treatment during an IVF cycle was also significantly elevated in the 10 to 16 mm follicles (p<0.01, 231 
Fig. 3C). In contrast to the untreated group, GH co-treated patients showed down-regulation of 232 
granulosal LHR density in follicles between 16 and 19 mm in diameter  (p<0.005, Fig. 3C). 233 
  234 
The level of BMPR1B was significantly increased in IVF patients receiving GH in 10 mm, 14 mm 235 
and 16 mm follicles compared to the same age patients of 39+ y with an ovarian reserve of D & E 236 
without GH (p<0.001, p<0.005, p<0.05, respectively; Fig.4D). 237 
Granulosal BMPR1B density was significantly higher in 10 mm, follicles from the GH co-treated 238 
patients compared to the larger pre-ovulatory follicles of either 16 mm or 19 mm (p< 0.05, Fig. 3D). 239 
In contrast, to the untreated group, GH co-treated patients showed down-regulation of granulosal 240 
BMPR1B density in the largest follicles of 16 to 19 mm (p<0.05,  p<0.05, respectively; Fig. 3D) 241 
 242 
When the follicles sizes are combined, the average granulosal density for GHR, FSHR, LHR and 243 
BMPR1B was significantly higher in the GH treated group with the same ovarian reserve and age 244 
(Fig. 3 A-D Inset, p<0.005).  245 
 246 
Growth hormone co-treatment and pregnancy rate in IVF patients 247 
The number of pregnancies was calculated based on the number of embryos that were transferred to 248 
the patients, which included subsequent FET cycles of cryo preserved embryos. 249 
The number of FET cycles was not significantly different between groups of patient. There was a 250 
significant difference in the pregnancy rate in GH treated patients compared to the same age and 251 
ovarian reserve patients without GH co-treatment (p=0.003; Fig. 5.). The number of live births per 252 
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embryo transfer was also significantly greater in the GH co-treated older age group compared to the 253 
equivalent age and ovarian reserve (p=0.0406, Fig. 6). The level of oestrogen and progesterone in 254 
serum and follicular fluid was not significantly different when comparing GH treatment in the 255 
equivalent older patient group of 39+ y. 256 
 257 
Serum & Follicular Fluid & GH co-treatment 258 
The results from the current study indicate that the GH co-treatment did not alter the oestrogen level 259 
of the 39+ year group cohort with an ovarian reserve of D or E during an IVF cycle (Supplementary 260 
Fig 2A). Furthermore, neither the ratio of oestrogen was not altered, nor the levels of oestrogen 261 
secreted, based on either the total number of follicles or the number of follicles greater than 14 mm 262 
present in the ovary at the time of collection, which were not significantly different. In addition, the 263 
follicular fluid concentration of oestrogen, progesterone, FSH, or testosterone was not significantly 264 
different to the age matched patients with a similar ovarian reserve that were co-treated with GH 265 
(Supplementary Fig 2B).  266 
Discussion  267 
GHRs are predominantly found on the granulosa cell membrane surface and in the endoplasmic 268 
reticulum, and to a lesser degree, but commonly, in the nuclear membrane of highly prolific cells (46, 269 
47). The GHR is regulated by GH binding proteins, which are secreted from the GHR, and by other 270 
growth factors indirectly such as FSH, BMPs and somatostatin (48, 49). In the current study, GH 271 
treatment induced a direct change to the receptor expression of GHR itself and indirectly to the other 272 
receptors FSHR, LHR and BMPR1B.  273 
 274 
In support of the clinical data on ageing, human granulosa receptor density and dysregulation of 275 
FSHR, LHR and BMPR1B has been associated with ovarian depletion and reduced fertility (30, 31). 276 
We now provide additional data in support of a reversal of the dysregulated receptor expression 277 
observed in older patients that occurs when they are treated with GH. In addition, depletion of the 278 
ovarian reserve was accompanied by a reduction in GHR density, whereas GH co-treatment during 279 
IVF increased the receptor density in older women who had a reduced ovarian reserve. These 280 
findings provide a possible cellular regulatory mechanism involved in the poor pregnancy and live 281 
birth rate in the older 39-45 y patients and reported by others (15, 16, 50-55) and reviewed by (56-282 
58).  283 
 284 
Evidence from our previously published work and the current study suggest that ovarian reserve and 285 
age are associated with reduced and dysregulated levels of receptor expression on granulosa cells. 286 
Therefore, the influence of age and ovarian reserve of subjects or animals needs to be considered as a 287 
confounding variable in previous studies.  In heifers, GH may not have resulted in any change to 288 
FSH and LH receptor binding because the cows were young, with an uncompromised ovarian reserve 289 
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and a sufficient receptor density (59). The effect of GH co-treatment on receptor density in patients 290 
with a good ovarian reserve for age remains at this time unknown. 291 
 292 
While GH increased the receptor expression on granulosa cells from the larger follicles, it had no 293 
effect on the FSHR and LHR density at the critical time of dominant follicle selection (smallest 294 
follicles of 4 mm). Previously, a poor ovarian response to rFSH stimulation has been associated with 295 
reduced granulosal FSHR expression (37). However, GH co-treatment was found not to alter the 296 
FSHR density in small bovine follicles, which is consistent with our findings for small human 297 
follicles (60). The lack of effect on FSHR and LHR expression of small pre-ovulatory follicles may 298 
explain why the number of oocytes collected was not increased in the current human model and 299 
others (56).  300 
 301 
Conversely, animal studies have reported an increase in oocyte number (61-65) . For example, even 302 
though more small bovine antral follicles were produced after 45 days of GH treatment in a natural 303 
cycle, the granulosal FSHRs and LHRs from pre-ovulatory bovine follicles were not affected (59, 304 
60). This is surprising; however, the receptor binding studies were determined only for the three 305 
largest follicles from each cow. Therefore, the expected pre-ovulatory down-regulation of these large 306 
follicles would have reduced FSHR expression which would confound these results. Added to this 307 
the receptor binding was not measured in any of the smaller follicles. In other studies, GH treatment 308 
increased the receptors in the rat (66) however; in the pig the receptor expression was reduced (67). 309 
In our human model, small antral follicles had high levels of FSHR followed by down-regulation 310 
which coincides with dominant follicle selection. The high level of FSHRs induce LHR expression in 311 
a natural cycle to ensure recruitment to the dominant cohort of follicles (68). In a natural cycle, 312 
pituitary secreted FSH is reduced at this critical time, whereas in an IVF cycle; rFSH is abundant; 313 
therefore the densities of the gonadotrophin receptors (FSHR and LHR) are pivotal in regulating 314 
follicle growth and dominance. 315 
 316 
Patients with a reduced ovarian reserve have a poorer response to rFSH treatment in IVF, and 317 
produce oocytes of poorer quality (37). The poor responder group of patients also have an associated 318 
high risk of foetal aneuploidy that has been correlated to ovarian reserve (69). Recently published 319 
data have shown that GH co-treatment increases the pregnancy rate by a suggested improvement in 320 
oocyte quality, rather than the quantity of follicles recruited (15, 16).  321 
 322 
If the oocyte number is not significantly different in the GH treated older women, then the focus 323 
shifts to the effect of GH on the quality of the oocyte. Regulation of proliferation, steroid production, 324 
luteinisation, ovulation, and recommencement of meiosis fundamentally resides with the functional 325 
expression of receptors in the follicle cells and oocyte.  326 
 327 
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A decline in granulosal BMPR1B and FSHR density occurred at the time of cyclic dominant follicle 328 
selection, and again during the terminal stage of folliculogenesis, in young (23-30 years) IVF patients 329 
with good ovarian reserve (30, 31). Older patients (39+ years) with poor ovarian reserve experienced 330 
a reversal of this pattern (30, 31). In addition, the LHR density failed to be down-regulated during 331 
pre-ovulatory maturation in the 39+ year group, and was reduced with ovarian reserve (31).  332 
 333 
In the present study, we report increased granulosa cell GHR density in different sized follicles from 334 
IVF patients undergoing conventional ovarian stimulation in young compared to older women with a 335 
reduced ovarian reserve. In addition, we report increased granulosal GHR, FSHR, LHR, and 336 
BMPR1B receptor density in older, poor ovarian reserve patients treated with GH. Importantly, the 337 
women treated with GH demonstrated receptor expression down-regulation in the largest follicles. 338 
The down-regulation would be essential for maturation of the ovulatory follicles, luteinisation and a 339 
shift to the luteal phase. 340 
 341 
In addition, the increased granulosal LHR density observed in the GH co-treated patients would have 342 
the potential to increase the sensitivity during the hCG/LH surge to trigger final maturation and 343 
ovulation of the oocyte (70, 71). The improved sensitivity may give rise to improved oocyte quality 344 
and live birth rate. In support of the  link between receptor density and maturation, a previous 345 
electron microscopy study revealed that oocytes that did not fertilise had reduced levels of granulosal 346 
luteinisation and were less responsive to hCG, which binds to the LHR (72).  347 
 348 
Conclusion 349 
The complexity and limitations of a largely observational, in vivo study in humans makes it difficult 350 
to define the cellular mechanism through which numerous growth factors and pathways contribute to 351 
the regulation of follicular growth and differentiation. However, the present study has generated 352 
evidence suggesting several cellular mechanisms that could contribute to the improved oocyte quality 353 
observed in GH co-treated IVF patients with a poor ovarian reserve.  354 
 355 
GH co-treatment increased granulosal GHR density that would increase GHR-JAK-STAT activity, 356 
and result in an increase in the intermediate products of transcription. This, in turn, could be 357 
mechanistically linked to the corresponding increase in gonadotrophin receptors and BMPR1B 358 
density observed in GH co-treated patients. GH co-treatment did not alter the gonadotrophin receptor 359 
density of the small follicles, and would therefore account for the lack of improvement in the number 360 
of follicles recruited during dominant follicle selection.  361 
 362 
In contrast, GH co-treatment also restored the pre-ovulatory down-regulation of FSHR, BMPR1B 363 
and LHR density, which may improve the maturation process of luteinisation in GH co-treated 364 
patients with reduced ovarian reserve. Combined with the latter, an increase in LHR density may 365 
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improve follicle development and provide another possible cellular mechanism responsible for the 366 
improved pregnancy and live birth rate. Objectively, we remain uncertain whether the beneficial 367 
action is mediated via improved oocyte quality or other responses such as endometrial receptivity. 368 
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Fig. 1  Validation of immunofluorescent labelling  599 
A. Subtraction of nonspecific binding (red) and auto-fluorescence (green) at ~10³; granulosa cell. B. Live 600 
granulosa cells, unstained control for GHR auto-fluorescence (blue) compared to positive fluorescent signal 601 
measurement (box). Gated and removed CD45 positive cells (circle) also confirmed binding specificity 602 
(Saizen, Merck Serono, Australia). C. Live human granulosa cells with positive fluorescence for GH receptor 603 
(a & b), and pre-absorbed GH for negative control and binding specificity of GHR (c & d). Bar 10 µm.  604 
 605 
Fig. 2 Granulosal GHR density and ovarian reserve depletion. 606 
GHR expression density on granulosa cells collected from patients during IVF treatment with a range of 607 
ovarian reserves of follicles, A. 23-30 y patient group, B. 31-34 y patient group, C. 35-38 y patient group, D. 608 
39+ y patient group. Ovarian reserve was measured indirectly by the antral follicle count (AFC). AFC is the 609 
number of follicles between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained 610 
using an average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein 611 
expression. The number within the column represents the number of follicles analysed for that group. The data 612 
were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for 613 
follicular size. Values in graphs are means ± S.E.M., and differences were considered significant if *p<0.05, 614 
**p<0.01 and ***p<0.005.  615 
 616 
Fig. 3 Follicle size and the granulosa cell density of GHR, FSHR, BMPR1B and LHR in 617 
poor response 39+ y patients co-treated with GH  618 
Follicles of different sizes were individually collected and analysed. Granulosa receptor density during an IVF 619 
cycle with or without GH co-treatment was measured by flow cytometry.  A. GHR, B. FSHR, C. LHR and D. 620 
BMPR1B. The number within the column represents the number of follicles analysed for that follicle size. Inset 621 
A Combined follicles of different sizes-GHR. Inset  B FSHR, Inset C LHR, and Inset D. The number within the 622 
column represents the number of follicles analysed.  Ovarian reserve measured indirectly by the antral follicle 623 
count (AFC). AFC is the number of follicles between 2-10 mm on day 2-5 of a cycle. Mean fluorescent 624 
intensity (MFI) was obtained using an average of ~8000 granulosa cells per follicle for the direct measurement 625 
of receptor protein expression. The data were subjected to statistical verification using one-way ANOVA with 626 
an uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± S.E.M., and differences were 627 
considered significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001.  628 
 629 
Fig. 4 GH associated pregnancy and live birth outcome 630 
A. The effect of GH treatment on pregnancy rate during IVF treatment.  B. The effect of GH treatment on 631 
pregnancy rate during IVF treatment. The data were subjected to statistical verification using chi square. The 632 
chi-square statistic p-value is p=0.0033. The data were based on the number of embryos transferred per patient 633 
age group or treatment, including subsequent frozen embryo cycles (FET). One patient with an ectopic 634 
pregnancy (classed as miscarriage) was present in the 23-30 y and the 35-38 y groups. Patients were selected 635 
randomly in a prospective regimen. 636 
  637 
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 638 
 639 
 640 
Table 1 Patient ovarian reserve, based on antral follicle count (AFC)  641 
¹ Typical Ovarian Reserve for age group 642 
² Ovarian reserve measured indirectly by the Antral Follicle Count (AFC). AFC is the number of follicles 643 
between 2-10 mm on day 2-5 of a cycle: group A+ = 30-39 follicles; group A = 20-29   644 
follicles; group B = 13-19 follicles; group C = 9-12 follicles, group D = 5-8 follicles; group E = ≤4 follicles. 645 
Follicle count is based on the combined total from both ovaries to determine AFC. The number of follicles 646 
aspirated from patients from the specified ovarian reserve group. 647 
³ CCF-Number of patients with complete failed fertilisation compared to same age group without GH 648 
4 Percentage per total number of embryos transferred 649 
5 The average number of oocytes collected at TVOA for the age group 650 
ₐ One patient with an ectopic pregnancy (classed as miscarriage) 651 
All subsequent frozen embryo cycles (FET) cycles were included in the analysis therefore the data was based 652 
on number of embryos transferred. 653 
**p=0.003, *p=0.041 Chi square test (d) =+GH 39+ y compared to (c) = 39+ y patient groups. 654 
  655 
Age 
years 
IVF 
patient 
Total   
follicle 
Ovarian 
reserve¹ 
Ovarian Reserve Group² 
Number of follicles  
collected per group 
 Oocyte quality  
 
 Fertility 
N (%)4  
    A+ A B C D E 
 #5 CCF³  ET  Not Pregnant Pregnant 
 
Miscarriage Live 
Birth 
21-30ₐ 10 68 20-40 26 42 - - - -  10 0 12  4(33) 8(67) 3(37) 5(42) 
31-34 12 96 13-29 - 48 23 16 9 - 
 8 0 15  9(60) 7(47) 1(14) 6(40) 
35-38ₐ 12 108 9-19 - 6 46 17 34 -  9 0 16  5(31) 11(68) 5(46) 4(25) 
39-45 19 131 3-8 - - 42 5 64 19 
 7 3 25  22(88) 3(12c) 2(68) 1(4c) 
+GH39-45 11 48 3-8 - - - - 25 23 
 4.5 3 10  4(40) 6(60d)** 4(68) 2(20d)* 
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